In 2017, the CANTOS trial, using the IL-1β monoclonal antibody canakinumab, also demonstrated the efficacy of IL-1β inhibitor treatment in decreasing the risk of myocardial infarction (MI), indicating that anti-inflammatory therapy is an effective strategy in CVD. The gene discussed is IL1B; the disease is myocardial infarction.